Last updated 2026-07-19
- Raised Seed round, Dec 2020
- Raised grant, Nov 2020
Total raised
—
Last: Undisclosed Round 2020-11
Stage
Seed
Founded
2020
Headcount
6
HQ
, Israel
Sector
Health Tech & Life Sciences
About
A2i Therapeutics is developing novel small-molecule immuno-oncology agents. The company was formed as a joint venture between FutuRx, an Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies, and Atomwise, a US-based company using artificial intelligence for small-molecule drug discovery. The partnership will leverage Atomwise's AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target.
Funding history · 2 rounds · — total
2020-12
Seed
Undisclosed
FutuRxJohnson & Johnson Innovation (JJDC, Inc.)Takeda VenturesOrbiMed PartnersLeaps by BayerIsraeli Innovation AuthorityRMGLOBAL Healthcare Fund Management
2020-11
Grant
Undisclosed
carried: prior grant (not re-verifiable vi…
Q&A
- What is A2i Therapeutics developing?
- A2i Therapeutics is developing novel small-molecule immuno-oncology agents.
- When was A2i Therapeutics founded?
- A2i Therapeutics was founded in November 2020.
- What is the primary sector of A2i Therapeutics?
- The primary sector of A2i Therapeutics is Health Tech & Life Sciences.
- How many employees does A2i Therapeutics have?
- A2i Therapeutics has 1-10 employees.
- Which entities formed A2i Therapeutics as a joint venture?
- A2i Therapeutics was formed as a joint venture between FutuRx, an Israeli biotechnology incubator, and Atomwise, a US-based company using artificial intelligence for drug discovery.
- What is the purpose of the partnership between FutuRx and Atomwise for A2i Therapeutics?
- The partnership leverages Atomwise's AI platform to target a key protein involved in controlling the innate immune response, which is a potential immuno-oncology target.
- Which investors participated in A2i Therapeutics' funding rounds in November 2020?
- In November 2020, A2i Therapeutics received funding from the Israel Innovation Authority and RMGP Biopharma Investment Fund.
- What is the current status of A2i Therapeutics?
- A2i Therapeutics is currently non-active and ceased to operate in July 2026.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
oncologydrug-discoveryimmunologybiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | a2i-tx.com |
|---|
Identifiers & details
| Founded | 2020-11 |
|---|---|
| Employees (exact) | 6 |